From 1 June 2019, faculty research that qualifies for an Exemption may be reviewed and approved by a Departmental Ethics Review Committee (DERC). This applies to social, behavioural and educational research (SBER) that is of minimal risk, but excludes any human biomedical research (HBR) that falls within section 3 of the Human Biomedical Research Act (HBRA).
All student and faculty research involving humans as research participants must be subject to ethics review by either the NUS Institutional Board (NUS-IRB) or the Department. The Department Ethics Review Committee (DERC) was set up in May 2017 as a representative of the Head of Department to review student research, and as of July 2019, faculty research as well. They will determine whether the research can be exempted or expedited (minimal risk projects) or referred to the NUS-IRB for review based on the risk to the participants. However, all human biomedical research as defined by section 3 of the Human Biomedical Research Act (HBRA) 2015 must be referred to the NUS-IRB for review.
Human Biomedical Research (HBR) and research that cannot be approved by DERC must be submitted to NUS-IRB via iRIMS.
Department of Pharmacy DERC was set up to expedite the approval process for educational research that qualifies for exemption. Educational research that qualifies for an Exemption may be reviewed and approved by the DERC. This applies to social, behavioural and educational research (SBER) that is of minimal risk, but excludes any human biomedical research (HBR) that falls within section 3 of the Human Biomedical Research Act (HBRA). As part of the review process, the DERC will determine whether the research can be exempted or referred to the NUS Institutional Review Board (NUS-IRB) for review based on the risk to the research participants.
Effective from 8 October 2024, DERCs will be authorized to review faculty research studies that are no more than minimal risk which qualify for Exemption, and are funded by overseas academic research organizations, Singapore Government agencies, or Singapore Government-owned entities, with grant amounts up to $180,000. This is in line with the existing policy for studies funded by MOE, A*STAR and MOH. For faculty research that qualifies for Exemption and is funded by other external sources, such as commercial companies, please submit your applications directly to the NUS-IRB for ethics review. In cases of uncertainty, the Principal Investigator (PI) should submit the application to the NUS-IRB.
This DERC review is further breakdown into 2 categories.
PI will need to review the general information and guideline IRB-GUIDE-018 Ethics Review of Student Research V8 2022-10-31 and initiate a new submission via the DERC Review and Approval Management (DREAM) App (DERC Review and Approval Management App – Power Apps)
PI may need to fill in the form below as applicable and attached to the relevant section of your study submission in DREAM.
PISCF IRB-GUIDE-S03 – V4 2020-05-28 -> need to fill up and submit (If applicable)
*Undergraduate students cannot be PIs.
PI will need to review the general information and guidelines on
1. IRB-GUIDE-022 Ethics Review of Faculty Research by DERC V3 2022-10-31 -> General information/guidelines
2. SBER Guidelines IRB-GUIDE-S02 – IRB Exemption Form V2.1 2017-08-22 -> General information/guidelineIRB-GUIDE-018
and initiate a new submission via the DERC Review and Approval Management (DREAM) App (DERC Review and Approval Management App – Power Apps)


The meaning of “human biomedical research” is defined by section 3, HBRA, which provides:
3.—(1) In this Act, “human biomedical research” means the research specified in subsection (2) or (3) but subject to subsection (4).
(2) Any research that is intended to study —
(a) the prevention, prognostication, diagnosis or alleviation of any disease, disorder or injury affecting the human body;
(b) the restoration, maintenance or promotion of the aesthetic appearance of human individuals through clinical procedures or techniques; or
(c) the performance or endurance of human individuals,
where the research involves —
(i) subjecting an individual to any intervention (including any wilful act or omission) that has a physical, mental or physiological effect (whether temporary or permanent) on the body of the individual;
(ii) the use of any individually-identifiable human biological material; or
(iii) the use of any individually-identifiable health information.
(3) Any research that involves —
(a) human gametes or human embryos;
(b) cytoplasmic hybrid embryos;
(c) the introduction of any human-animal combination embryo into an animal or a human;
(d) the introduction of human stem cells (including induced pluripotent stem cells) or human neural cells into an animal at any stage of development (including a prenatal animal foetus or animal embryo); or
(e) any entity created as a result of any process referred to in paragraph (c) or (d).
(4) Subsections (2) and (3) do not apply to such research, studies or activities that are specified in the Second Schedule.
(5) For the purposes of this Act, human biomedical research is treated as conducted under the supervision and control of a research institution if the research institution is identified as the research institution for that research and that research has been reviewed by an institutional review board appointed by that research institution.”
[1] Any systematic investigation with the intention of developing or contributing to generalizable knowledge.
[2] See SBER Guidelines on IRB Exemption Form at http://nus.edu.sg/research/irb/guidelines/sber-guidelines to determine if a study could be exempted.
[3] Risk is considered minimal where the probability and magnitude of harm or discomfort anticipated in the research are not greater, in and of themselves, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
[4] Refers to subjects who may be unduly coerced or influenced to participate (e.g. children, prisoners, pregnant women, cognitively impaired persons, or educationally disadvantaged persons who require special consideration to protect their welfare.)
[5] Deception occurs when (i) a researcher deliberately gives subjects false information about some aspect of the research; or (ii) knowingly withholds information about the real purpose or nature of the research (i.e. incomplete disclosure or concealment).
3.—(1) In this Act, “human biomedical research” means the research specified in subsection (2) or (3) but subject to subsection (4).
(2) Any research that is intended to study —
(a) the prevention, prognostication, diagnosis or alleviation of any disease, disorder or injury affecting the human body;
(b) the restoration, maintenance or promotion of the aesthetic appearance of human individuals through clinical procedures or techniques; or
(c) the performance or endurance of human individuals,
where the research involves —
(i) subjecting an individual to any intervention (including any wilful act or omission) that has a physical, mental or physiological effect (whether temporary or permanent) on the body of the individual;
(ii) the use of any individually-identifiable human biological material; or
(iii) the use of any individually-identifiable health information.
(3) Any research that involves —
(a) human gametes or human embryos;
(b) cytoplasmic hybrid embryos;
(c) the introduction of any human-animal combination embryo into an animal or a human;
(d) the introduction of human stem cells (including induced pluripotent stem cells) or human neural cells into an animal at any stage of development (including a prenatal animal foetus or animal embryo); or
(e) any entity created as a result of any process referred to in paragraph (c) or (d).
(4) Subsections (2) and (3) do not apply to such research, studies or activities that are specified in the Second Schedule.
(5) For the purposes of this Act, human biomedical research is treated as conducted under the supervision and control of a research institution if the research institution is identified as the research institution for that research and that research has been reviewed by an institutional review board appointed by that research institution.”
Please refer to the flowchart below that illustrates the above.
[1] Any systematic investigation with the intention of developing or contributing to generalizable knowledge.
[2] Risk is considered minimal where the probability and magnitude of harm or discomfort anticipated in the research are not greater, in and of themselves, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
[3] Refers to subjects who may be unduly coerced or influenced to participate (e.g. children, prisoners, pregnant women, cognitively impaired persons, or educationally disadvantaged persons who require special consideration to protect their welfare.)
[4] Deception occurs when (i) a researcher deliberately gives subjects false information about some aspect of the research; or (ii) knowingly withholds information about the real purpose or nature of the research (i.e. incomplete disclosure or concealment).
